ABSTRACT
Epigenetic proteins containing YEATS domains (YD) are an emerging target class in drug discovery. Described herein are the discovery and characterization efforts associated with PFI-6, a new chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). For hit identification, fragment-like mimetics of endogenous YD ligands (crotonylated histone-containing proteins), were synthesized via parallel medicinal chemistry (PMC) and screened for MLLT1 binding. Subsequent SAR studies led to iterative MLLT1/3 binding and selectivity improvements, culminating in the discovery of PFI-6. PFI-6 demonstrates good affinity and selectivity for MLLT1/3 vs. other human YD proteins (YEATS2/4) and engages MLLT3 in cells. Small-molecule X-ray co-crystal structures of two molecules, including PFI-6, bound to the YD of MLLT1/3 are also described. PFI-6 may be a useful tool molecule to better understand the biological effects associated with modulation of MLLT1/3.
Subject(s)
Histones , Nuclear Proteins , Humans , Nuclear Proteins/metabolism , Histones/metabolism , Protein Domains , Drug Discovery , Neoplasm Proteins/metabolism , Transcription Factors/metabolismABSTRACT
A general and convenient procedure for the synthesis of azinones is presented. Cyclopropylmethanol is readily introduced onto various azines where it functions as both a protecting group and surrogate for hydroxyl. After acidic deprotection, under mild reaction conditions, the corresponding azinones are formed and isolated in excellent yields. >20 examples are included along with a discussion of reaction optimization, scope, and mechanism.
ABSTRACT
Our previous work on the optimization of a new class of small molecule PCSK9 mRNA translation inhibitors focused on empirical optimization of the amide tail region of the lead PF-06446846 (1). This work resulted in compound 3 that showed an improved safety profile. We hypothesized that this improvement was related to diminished binding of 3 to non-translating ribosomes and an apparent improvement in transcript selectivity. Herein, we describe our efforts to further optimize this series of inhibitors through modulation of the heterocyclic head group and the amine fragment. Some of the effort was guided by an emerging cryo electron microscopy structure of the binding mode of 1 in the ribosome. These efforts led to the identification of 15 that was deemed suitable for evaluation in a humanized PCSK9 mouse model and a rat toxicology study. Compound 15 demonstrated a dose dependent reduction of plasma PCSK9 levels. The rat toxicological profile was not improved over that of 1, which precluded 15 from further consideration as a clinical candidate.
ABSTRACT
[This corrects the article DOI: 10.1371/journal.pbio.2001882.].
ABSTRACT
The atypical chemokine receptor C-X-C chemokine receptor type 7 (CXCR7) is an attractive therapeutic target for a variety of cardiac and immunological diseases. As a strategy to mitigate known risks associated with the development of higher molecular weight, basic compounds, a series of pyrrolidinyl-azolopyrazines were identified as promising small-molecule CXCR7 modulators. Using a highly enabled parallel medicinal chemistry strategy, structure-activity relationship studies geared towards a reduction in lipophilicity and incorporation of saturated heterocycles led to the identification of representative tool compound 20. Notably, compound 20 maintained good potency against CXCR7 with a suitable balance of physicochemical properties to support in vivo pharmacokinetic studies.
Subject(s)
Drug Discovery , Immunologic Factors/chemical synthesis , Immunologic Factors/pharmacology , Receptors, CXCR/antagonists & inhibitors , Animals , Drug Delivery Systems , Drug Design , Immunologic Factors/pharmacokinetics , Male , Mice , Mice, Inbred C57BL , Models, Molecular , Molecular Structure , Signal Transduction , Structure-Activity RelationshipABSTRACT
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ribosome to stall around codon 34, mediated by the sequence of the nascent chain within the exit tunnel. We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol levels in rats following oral dosing. Using ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PCSK9 translation. The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability of the human ribosome that allows small molecules to specifically block translation of individual transcripts.
Subject(s)
Protein Biosynthesis/drug effects , Ribosomes/drug effects , Animals , Cell Line , Cell-Free System , Cholesterol/blood , Escherichia coli/genetics , HeLa Cells , Heterocyclic Compounds, 4 or More Rings/pharmacology , Humans , Male , Mass Spectrometry , Molecular Targeted Therapy , Proprotein Convertase 9/blood , Proprotein Convertase 9/genetics , Protein Biosynthesis/physiology , Rabbits , Rats , Rats, Sprague-Dawley , Ribosomes/metabolism , Ribosomes/physiologyABSTRACT
Molecules containing trifluoromethoxyaryl groups are of interest in pharmaceutical, agrochemical, and materials science research, due to their unique physical and electronic properties. Many of the known methods to synthesize aryl trifluoromethyl ethers require harsh reagents and highly controlled reaction conditions and rarely occur when heteroaromatic units are present. The two-step O-trifluoromethylation of phenols via aryl xanthates is one such method that suffers from these drawbacks. Herein, we report a method for the synthesis of aryl trifluoromethyl ethers from phenols by the facile conversion of the phenol to the corresponding aryl and heteroaryl xanthates with newly synthesized imidazolium methylthiocarbonothioyl salts and conversion of these xanthates to the trifluoromethyl ethers under mild reaction conditions.
Subject(s)
Ethers/chemical synthesis , Hydrocarbons, Fluorinated/chemical synthesis , Phenols/chemistry , Xanthines/chemistry , Ethers/chemistry , Hydrocarbons, Fluorinated/chemistry , Molecular StructureABSTRACT
A series of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides were identified as small molecule PCSK9 mRNA translation inhibitors. Analogues from this new chemical series, such as 4d and 4g, exhibited improved PCSK9 potency, ADME properties, and in vitro safety profiles when compared to earlier lead structures.
Subject(s)
Amides/chemistry , PCSK9 Inhibitors , Piperidines/chemistry , Protease Inhibitors/chemistry , Amides/metabolism , Amides/pharmacology , Animals , Cell Membrane Permeability/drug effects , Crystallography, X-Ray , Dogs , Humans , Inhibitory Concentration 50 , Madin Darby Canine Kidney Cells , Molecular Conformation , Proprotein Convertase 9/metabolism , Protease Inhibitors/metabolism , Protease Inhibitors/pharmacology , Structure-Activity RelationshipABSTRACT
Targeting of the human ribosome is an unprecedented therapeutic modality with a genome-wide selectivity challenge. A liver-targeted drug candidate is described that inhibits ribosomal synthesis of PCSK9, a lipid regulator considered undruggable by small molecules. Key to the concept was the identification of pharmacologically active zwitterions designed to be retained in the liver. Oral delivery of the poorly permeable zwitterions was achieved by prodrugs susceptible to cleavage by carboxylesteraseâ 1. The synthesis of select tetrazole prodrugs was crucial. A cell-free inâ vitro translation assay containing human cell lysate and purified target mRNA fused to a reporter was used to identify active zwitterions. Inâ vivo PCSK9 lowering by oral dosing of the candidate prodrug and quantification of the drug fraction delivered to the liver utilizing an oral positron emission tomography 18 F-isotopologue validated our liver-targeting approach.
Subject(s)
Liver/drug effects , PCSK9 Inhibitors , Proprotein Convertase 9/biosynthesis , Small Molecule Libraries/pharmacology , Dose-Response Relationship, Drug , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Liver/enzymology , Liver/metabolism , Molecular Structure , Proprotein Convertase 9/metabolism , Small Molecule Libraries/chemistry , Structure-Activity RelationshipABSTRACT
Optimization of a high-throughput screening hit led to the discovery of a new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as highly potent agonists of TGR5. This novel chemotype was rapidly developed through iterative combinatorial library synthesis. It was determined that in vitro agonist potency correlated with functional activity data from human peripheral blood monocytes.
Subject(s)
Amides/chemical synthesis , Amides/pharmacology , Pyrazoles/chemical synthesis , Pyrazoles/pharmacology , Receptors, G-Protein-Coupled/agonists , Amides/chemistry , Combinatorial Chemistry Techniques , Humans , Pyrazoles/chemistry , Structure-Activity RelationshipABSTRACT
A series of small-molecule YEATS4 binders have been discovered as part of an ongoing research effort to generate high-quality probe molecules for emerging and/or challenging epigenetic targets. Analogues such as 4d and 4e demonstrate excellent potency and selectivity for YEATS4 binding versus YEATS1,2,3 and exhibit good physical properties and in vitro safety profiles. A new X-ray crystal structure confirms direct binding of this chemical series to YEATS4 at the lysine acetylation recognition site of the YEATS domain. Multiple analogues engage YEATS4 with nanomolar potency in a whole-cell nanoluciferase bioluminescent resonance energy transfer assay. Rodent pharmacokinetic studies demonstrate the competency of several analogues as in vivo-capable binders.
Subject(s)
Gene Expression Regulation , Protein Processing, Post-Translational , Protein Domains , Acetylation , Epigenesis, GeneticABSTRACT
Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has advanced into clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis, are described herein. Ervogastat is a first-in-class DGAT2 inhibitor that addressed potential development risks of the prototype liver-targeted DGAT2 inhibitor PF-06427878. Key design elements that culminated in the discovery of ervogastat are (1) replacement of the metabolically labile motif with a 3,5-disubstituted pyridine system, which addressed potential safety risks arising from a cytochrome P450-mediated O-dearylation of PF-06427878 to a reactive quinone metabolite precursor, and (2) modifications of the amide group to a 3-THF group, guided by metabolite identification studies coupled with property-based drug design.
Subject(s)
Diacylglycerol O-Acyltransferase , Non-alcoholic Fatty Liver Disease , Humans , Drug Design , Liver Cirrhosis , Non-alcoholic Fatty Liver Disease/drug therapyABSTRACT
Dysfunction of YEATS-domain-containing MLLT1, an acetyl/acyl-lysine dependent epigenetic reader domain, has been implicated in the development of aggressive cancers. Mutations in the YEATS domain have been recently reported as a cause of MLLT1 aberrant reader function. However, the structural basis for the reported alterations in affinity for acetylated/acylated histone has remained elusive. Here, we report the crystal structures of both insertion and substitution mutants present in cancer, revealing significant conformational changes of the YEATS-domain loop 8. Structural comparison demonstrates that not only did such alteration alter the binding interface for acetylated/acylated histones, but the sequence alterations in the loop in T1 mutant may enable dimeric assembly consistent with inducing self-association behavior. Nevertheless, we show that also the MLLT1 mutants can be targeted by developed acetyllysine mimetic inhibitors with affinities similarly to wild-type. Our report provides a structural basis for the altered behaviors and a potential strategy for targeting oncogenic MLLT1 mutants.
Subject(s)
Mutation , Neoplasm Proteins/metabolism , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Humans , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Protein Conformation , Transcription Factors/chemistry , Transcription Factors/geneticsABSTRACT
High-throughput screening of the GSK compound collection against the P2Y(1) receptor identified a novel series of tetrahydro-4-quinolinamine antagonists. Optimal substitution around the piperidine group was pivotal for ensuring activity. An exemplar analog from this series was shown to inhibit platelet aggregation.
Subject(s)
Aminoquinolines/chemical synthesis , Aminoquinolines/pharmacology , Platelet Aggregation Inhibitors/chemical synthesis , Platelet Aggregation Inhibitors/pharmacology , Purinergic P2 Receptor Antagonists , Aminoquinolines/chemistry , Combinatorial Chemistry Techniques , Humans , Molecular Structure , Platelet Aggregation Inhibitors/chemistry , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2Y1 , Stereoisomerism , Structure-Activity Relationship , Thrombosis/drug therapyABSTRACT
C-X-C chemokine receptor type 7 (CXCR7) is involved in cardiac and immune pathophysiology. We report the discovery of a novel 1,4-diazepine CXCR7 modulator, demonstrating for the first time the role of pharmacological CXCR7 intervention in cardiac repair. Structure-activity-relationship (SAR) studies demonstrated that a net reduction in lipophilicity (log D) and an incorporation of saturated ring systems yielded compounds with good CXCR7 potencies and improvements in oxidative metabolic stability in human-liver microsomes (HLM). Tethering an ethylene amide further improved the selectivity profile (e.g., for compound 18, CXCR7 Ki = 13 nM, adrenergic α 1a Kb > 10â¯000 nM, and adrenergic ß 2 Kb > 10â¯000 nM). The subcutaneous administration of 18 in mice led to a statistically significant increase in circulating concentrations of plasma stromal-cell-derived factor 1α (SDF-1α) of approximately 2-fold. Chronic dosing of compound 18 in a mouse model of isoproterenol-induced cardiac injury further resulted in a statistically significant reduction of cardiac fibrosis.
Subject(s)
Acetamides/therapeutic use , Azepines/therapeutic use , Cardiotonic Agents/therapeutic use , Fibrosis/drug therapy , Heart Diseases/drug therapy , Receptors, CXCR/metabolism , Acetamides/chemical synthesis , Acetamides/chemistry , Acetamides/pharmacology , Animals , Azepines/chemical synthesis , Azepines/chemistry , Azepines/pharmacology , Cardiotonic Agents/chemical synthesis , Cardiotonic Agents/chemistry , Cardiotonic Agents/pharmacology , Dogs , Fibrosis/chemically induced , Heart Diseases/chemically induced , Humans , Hydrophobic and Hydrophilic Interactions , Isoproterenol , Madin Darby Canine Kidney Cells , Male , Mice, Inbred BALB C , Mice, Inbred C57BL , Microsomes, Liver/metabolism , Molecular Structure , Structure-Activity RelationshipABSTRACT
The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved by changes to two regions of the molecule. The last step in the synthesis of the congested amide center was enabled by three different routes. Subtle structural changes yielded significant changes in pharmacology and off-target margins. These efforts led to the identification of 7l and 7n with overall profiles suitable for in vivo evaluation. In a 14-day toxicology study, 7l demonstrated an improved safety profile vs lead 7f. We hypothesize that the improved safety profile is related to diminished binding of 7l to nontranslating ribosomes and an apparent improvement in transcript selectivity due to the lower strength of 7l stalling of off-target proteins.
Subject(s)
PCSK9 Inhibitors , Protease Inhibitors/chemistry , Protease Inhibitors/pharmacology , Animals , Drug Design , Male , Protease Inhibitors/adverse effects , Protease Inhibitors/metabolism , Rats , Rats, Sprague-Dawley , Safety , Structure-Activity RelationshipABSTRACT
A strategy for the structural modification of biologically important alkene-containing natural products via ring-opening olefin metathesis is described. Exposure of manzamine A 1 to the second-generation Grubbs catalyst in the presence of ethylene leads to the formation of 2 and 4. The antibacterial activity of the novel manzamine analogue 2 (IC50=0.10 nM) against Mycobacterium intracellulare is ca. 2-fold more potent than that of ciprofloxacin (IC50=0.18 nM), a drug that is frequently used against antibiotic-resistant infections.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/pharmacology , Carbazoles/chemical synthesis , Animals , Inhibitory Concentration 50 , Leishmania donovani/drug effects , Molecular Structure , Mycobacterium avium Complex/drug effects , Plasmodium falciparum/drug effectsABSTRACT
Compounds that contain the 1-heteroaryl-3-azabicyclo[3.1.0]hexane architecture are of particular interest to the pharmaceutical industry yet remain a challenge to synthesize. We report herein an expedient and modular approach to the synthesis of 1-heteroaryl-3-azabicyclo[3.1.0]hexanes by Suzuki-Miyaura and Chan-Evans-Lam coupling reactions of tertiary trifluoroborate salts. Our Suzuki-Miyaura cross-coupling protocol is compatible with a broad range of aryl and heteroaryl bromides and chlorides. The unprecedented Chan-Evans-Lam coupling of tertiary trifluoroborates allows the facile construction of 1-heteroaryl-3-azabicyclo[3.1.0]hexanes containing C-tertiary arylamines at the ring juncture.
ABSTRACT
Manzamine A represents an important lead structure for the development of novel antimalarial chemotherapies. The synthesis and biological evaluation of a group of simplified analogues of manzamine A, which were designed to examine the roles of the A and D rings and of both the relative stereochemistry and the orientation of the beta-carboline heterocycle on the antimalarial activity of manzamine A, are described. [structure: see text]
Subject(s)
Antimalarials , Carbazoles , Plasmodium falciparum/drug effects , Animals , Antimalarials/chemical synthesis , Antimalarials/chemistry , Antimalarials/pharmacology , Carbazoles/chemical synthesis , Carbazoles/chemistry , Carbazoles/pharmacology , Inhibitory Concentration 50 , Molecular Structure , Stereoisomerism , Structure-Activity RelationshipABSTRACT
[Structure: see text] The synthesis and biological evaluation of a series of analogues of manzamine A, representing partial structures of the pentacyclic ABCDE diamine core, is described. All new compounds were screened against Plasmodium falciparum and demonstrated attenuated antimalarial activity relative to that of manzamine A.